自体CIK细胞联合化疗治疗晚期非小细胞肺癌  

Treatment of Advanced Non-small Cell Lung Cancer by Chemotherapy Combined with Autologous Cytokine-induced Killer Cells

作　　者：杨轩璇[1] 蒋敬庭[1] 石亮荣[1] 邓海峰[1] 陆明洋[1] 李敏[1] 徐斌[1] 季枚[1] 张红宇[1] 吴昌平[1] 

机构地区：[1]苏州大学附属第三医院肿瘤生物诊疗中心,江苏常州213003

出　　处：《苏州大学学报（医学版）》2008年第2期237-240,共4页Suzhou University Journal of Medical Science

基　　金：江苏省社会发展计划资助项目[BS2005616];常州市科技局资助项目[CS2003207]

摘　　要：目的评价自体细胞因子诱导的杀伤细胞(CIK细胞)联合化疗治疗晚期非小细胞肺癌(NSCLC)的临床疗效。方法59例患者分成A组(自体CIK细胞联合TP方案化疗29例)与B组(单用TP方案化疗30例)。对两组的生活质量、免疫学反应、缓解率(RR)、疾病进展时间(TTP)与生存期进行观察比较。CIK细胞由自体外周血单个核细胞诱导产生。结果CIK细胞的数量与杀伤活性均在培养第14￣21天达到高峰。与B组相比,A组患者的免疫力与生活质量、疾病控制率(DCR)显著提高,中位生存时间(MST)明显延长,TTP与总生存期(OS)均明显延长,差异均有统计学意义(均P<0.05)。两组间RR差异无统计学意义(P>0.05)。结论自体CIK细胞回输安全、副作用小。CIK细胞联合化疗治疗晚期NSCLC能有效改善患者生活质量,并能延长生存期。Objective The clinical efficacy of chemotherapy was evaluated combined with cytokine-induced killer（CIK） cells biotherapy to advanced non-small cell lung cancer（NSCLC）, Methods Fifty-nine advanced NSCLC patients were fractionated group A （CIK cells biotherapy plus chemotherapy） and group B（chemotherapy alone）. The host cellular immune function, quality of life （QOL）, response rate（RR）, time to progression （TTP） and median survival time （MST） were compared between, the two groups. CIK cells were induced from autologous peripheral mononuclear cells. Results Amounts and cytotoxic activity of CIK cells reached the peak between days 14 to 21. The host immune function was increased and QOL was improved in patients in group B campared with group A, the disease control rate （DCR） was higher, the MST was longer, the TTP and overall survival（OS） were significantly prolonged. The RR has no significant difference between the 2 groups. Conclusion It is safe to patients by autologous CIK cells transfusion. Chemotherapy .combined with CIK cells has benefits for the patients suffering from advanced NSCLC, and there is advantage to chemotherapy alone in terms of QOL, DCR, TTP and survival.

关 键 词：肺肿瘤 细胞因子诱导的杀伤细胞 免疫治疗 疗效 

分 类 号：R734.2[医药卫生—肿瘤] R730.54[医药卫生—临床医学]